{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:10:21Z","timestamp":1781557821632,"version":"3.54.5"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1038\/s41375-023-01975-0","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T07:07:36Z","timestamp":1689923256000},"page":"1929-1932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0070-138X","authenticated-orcid":false,"given":"Paul J.","family":"Hengeveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-3125","authenticated-orcid":false,"given":"Hendrik","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-4517","authenticated-orcid":false,"given":"Cornelis A. M.","family":"van Bergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Quinten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mischa Y. L.","family":"Vervoordeldonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahija","family":"Ismailzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob S.","family":"Barendse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M. N.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus H. J.","family":"van Oers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-7039","authenticated-orcid":false,"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-3220","authenticated-orcid":false,"given":"Anton W.","family":"Langerak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-3547","authenticated-orcid":false,"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"1975_CR1","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2020007039","volume":"137","author":"A Agathangelidis","year":"2021","unstructured":"Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood. 2021;137:1365\u201376.","journal-title":"Blood"},{"key":"1975_CR2","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1073\/pnas.1913810117","volume":"117","author":"PC Maity","year":"2020","unstructured":"Maity PC, Bilal M, Koning MT, Young M, Van Bergen CAM, Renna V, et al. IGLV3-21\u221701 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc Natl Acad Sci USA 2020;117:4320\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1975_CR3","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood.2020008311","volume":"137","author":"F Nadeu","year":"2021","unstructured":"Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, Mart\u00edn S, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2021;137:2935\u201346.","journal-title":"Blood"},{"key":"1975_CR4","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1038\/s41375-022-01600-6","volume":"36","author":"PJ Hengeveld","year":"2022","unstructured":"Hengeveld PJ, Ertem YE, Dubois JMN, Mellink CHM, van der Kevie-Kersemaekers AM, Evers LM, et al. Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. Leukemia. 2022;36:1935\u20138.","journal-title":"Leukemia"},{"key":"1975_CR5","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3324\/haematol.2019.231027","volume":"105","author":"S Jaramillo","year":"2019","unstructured":"Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2019;105:2598\u2013607.","journal-title":"Haematologica"},{"key":"1975_CR6","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1182\/blood-2014-01-547737","volume":"123","author":"CH Geisler","year":"2014","unstructured":"Geisler CH, Van t\u2019Veer MB, Jurlander J, Walewski J, Tj\u00f8nnfjord G, It\u00e4l\u00e4 Remes M, et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood. 2014;123:3255\u201362.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01975-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01975-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01975-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T13:03:59Z","timestamp":1692968639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01975-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":6,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1975"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01975-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JMND has received research funding from Roche\/Genentech. APK has received research grants from Abbvie, AstraZeneca, BMS, Janssen and Roche Genentech and has performed Adboard activities for Abbvie, BMS, Janssen, LAVA and Roche Genentech. AWL has received research funding via an unrestricted grant from Roche-Genentech and speaker-fees from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche\/Genentech. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}